

APR. 8. 2004 9:03AM AVENTIS US PAT DEPT  
TO: US USPTO GENERAL

NO. 1321 P  
RECEIVED  
CENTRAL FAX CENTER

APR 08 2004

OFFICIAL

FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE

Applicants Docket Number:  
DEAV2001/0073 US NP

Applicants:  
WEITHMANN, et al.

Serial No.  
10/065, 944  
10/065, 944

Filing Date:  
12/09/2002

Title of Invention:  
PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID  
DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES

CERTIFICATE OF TRANSMISSION  
I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703-872-9306, on  
Date of Deposit: April 8, 2004  
Printed Name of Person Signing Certificate: Paul Irvine  
Signature: 

Total Number of Pages Sent: 3

Attorney: George G. Wang

Group Art Unit: 1624

Examiner: Habte, Kahsay

To:  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Fee Transmittal
<input type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Extension of Time Petition	<input checked="" type="checkbox"/> Other <u>Reply to Office Action</u>
<input type="checkbox"/> Issue Fee Transmittal & Advance Order	<input type="checkbox"/> Other _____
<input type="checkbox"/> Maintenance Fee Transmittal	

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6500, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)